The Future of Precision Medicine: What AlphaGenome Means for Clinical Diagnostics

Introduction

The sequencing of the human genome at the turn of the millennium marked the beginning of a new era in biology, providing the complete "book of life." Yet, for over two decades, our ability to read this book has been uneven. While the 2% of the genome that codes for proteins—the exome—is relatively well understood, the remaining 98% of non-coding DNA has remained largely opaque. These vast stretches of sequence, once dismissed as "junk DNA," are now known to contain the complex regulatory instructions that orchestrate the expression of genes, determining cellular identity, development, and response to environmental stimuli.

On January 28, 2026, researchers at Google DeepMind published a pivotal study in Nature, introducing AlphaGenome—a unified deep learning model designed to decode this regulatory landscape with unprecedented breadth and precision. AlphaGenome represents a paradigm shift in computational genomics. Unlike previous tools that were specialized for specific tasks or limited by trade-offs between sequence length and resolution, AlphaGenome processes DNA sequences of up to one million base pairs and simultaneously predicts 5,930 functional genomic tracks across 11 diverse modalities at single-base-pair resolution.

This report provides an exhaustive analysis of the AlphaGenome system. It explores the architectural innovations that enable long-range contextual learning, the novel "distillation" training paradigm that ensures efficiency, and the model's performance across a rigorous suite of benchmarks where it established new state-of-the-art standards in 25 out of 26 evaluations. Furthermore, this analysis delves into specific biological case studies—such as the elucidation of mechanisms driving T-cell acute lymphoblastic leukemia and the resolution of complex splicing variants—to demonstrate the model's practical utility. Finally, the report considers the broader implications of AlphaGenome for clinical diagnostics, therapeutic design, and the future of precision medicine, while weighing expert perspectives on its current limitations and potential.

1. The Biological Imperative: Illuminating the Dark Genome

To appreciate the significance of AlphaGenome, one must first understand the biological challenge it addresses. The human genome consists of approximately 3 billion base pairs of DNA, organized into chromosomes. However, the regions that directly template proteins—the genes—occupy only a tiny fraction of this space. The vast majority of the genome is non-coding, serving as the regulatory hardware of the cell.

1.1 The Complexity of Gene Regulation

Gene regulation is the process by which cells control the timing, location, and amount of gene expression. This regulation is mediated by a complex interplay of physical and chemical factors:

• Promoters: Regions located immediately upstream of a gene that initiate transcription.

• Enhancers: Distal regulatory elements that can be located tens or hundreds of thousands of base pairs away from their target genes. Enhancers loop physically in 3D space to contact promoters and boost transcription.

• Chromatin Accessibility: The genome is packaged around histone proteins into chromatin. For a gene to be active, the chromatin must be "open" or accessible to the cellular machinery.

• Splicing: As a gene is transcribed into RNA, non-coding segments (introns) are removed, and coding segments (exons) are stitched together. This process can be varied (alternative splicing) to produce different proteins from the same gene.

1.2 The Challenge of Variation

Genetic variation—differences in the DNA sequence between individuals—is the raw material of evolution and the root cause of genetic disease. While the medical community has become adept at interpreting variants within protein-coding genes (e.g., a mutation that breaks a specific enzyme), interpreting non-coding variants remains a formidable hurdle.

Genome-Wide Association Studies (GWAS) have identified thousands of genetic variants associated with complex diseases like diabetes, schizophrenia, and heart disease. Strikingly, over 90% of these variants lie in the non-coding genome.¹ These variants do not break proteins directly; instead, they subtly alter the regulatory code—perhaps weakening an enhancer, creating a new transcription factor binding site, or disrupting a splice site.

Historically, determining the function of these non-coding variants required laborious experimental assays. Computational prediction offered a faster alternative, but existing models were fragmented. A researcher might use one tool to predict splicing effects, another for chromatin accessibility, and a third for 3D structure, often grappling with conflicting outputs and incompatible data formats. Furthermore, older models faced a "resolution vs. context" trade-off: they could either look at a small window of DNA with high precision (missing distant enhancers) or look at a large window with low resolution (blurring the precise molecular mechanism).³

AlphaGenome was engineered to resolve these conflicts, offering a unified view of the regulatory genome that is both wide-angle and high-definition.

2. Architectural Innovations: Engineering the AlphaGenome

The capabilities of AlphaGenome are rooted in a novel neural network architecture that combines the strengths of several deep learning paradigms. The design philosophy emphasizes the integration of long-range information with local precision, a necessity for modeling biological phenomena that span multiple scales of length.

2.1 The Hybrid Backbone: U-Net and Transformers

At its core, AlphaGenome utilizes a hybrid backbone inspired by U-Net architectures, commonly used in image segmentation, augmented with Transformer blocks, the architecture powering modern large language models.⁴

The U-Net structure allows the model to process information at multiple resolutions. An "encoder" path progressively downsamples the genomic sequence, compressing the information into high-level abstract representations. This allows the model to recognize broad genomic features, such as large chromatin domains. Symmetrically, a "decoder" path upsamples these representations back to the original resolution, combining the high-level context with fine-grained details retained from the input.⁴ This structure ensures that the final output is at single-base-pair resolution, allowing the model to pinpoint the exact nucleotide responsible for a biological effect.

2.2 Breaking the Memory Barrier: Inter-Device Communication

A critical requirement for modeling gene regulation is the ability to analyze a large "context window." Enhancers can regulate genes located over 500,000 base pairs away. To capture these interactions, AlphaGenome processes input sequences of one million base pairs (1 Mb).¹

However, processing such a massive sequence with standard Transformer attention mechanisms is computationally prohibitive. The memory required for "attention"—where every part of the sequence looks at every other part—scales quadratically with sequence length. To overcome this, the AlphaGenome team implemented a strategy of sequence parallelism with inter-device communication.⁴

The 1 Mb input sequence is divided into smaller chunks, specifically 131-kilobase segments. These segments are distributed across multiple distinct accelerator chips (TPUs or GPUs). The innovation lies in the communication protocol: during the Transformer layers, these devices exchange information, allowing the attention mechanism to operate across the boundaries of the chunks.⁶ This effectively stitches the sequence back together in the model's computational space, enabling it to learn dependencies between genetic elements that are hundreds of thousands of base pairs apart without overwhelming the memory of a single device.⁵ This architecture allows AlphaGenome to "see" the distal enhancer and the target promoter simultaneously, a feat that smaller context models cannot achieve.

2.3 The Splicing Module: A Two-Dimensional Approach

One of the most biologically sophisticated components of AlphaGenome is its dedicated splicing module. Splicing is inherently a pairwise process: a splice donor site at the beginning of an intron must be paired with a splice acceptor site at the end. These sites can be separated by introns ranging from dozens to tens of thousands of bases.

Standard 1D sequence models struggle to explicitly represent this donor-acceptor logic. They often rely on the model "remembering" the donor as it scans linearly toward the acceptor. AlphaGenome, taking inspiration from the protein structure prediction model AlphaFold, introduces a Sequence-to-Pair projection block.⁵

This component converts the 1D sequence embeddings into a 2D pairwise representation. In this 2D matrix, every position in the sequence can be explicitly related to every other position. This allows the model to form a direct representation of the interaction between a specific donor and a specific acceptor.⁵ Crucially, this 2D branch is not an isolated add-on; it shares parameters and gradients with the main encoder. This means that when the model learns a sequence motif that influences splicing (e.g., an intronic splicing silencer), that knowledge propagates through both the 1D and 2D branches, refining the predictions for gene expression and protein binding simultaneously.⁵

This architectural choice allows AlphaGenome to predict three distinct aspects of splicing with high accuracy:

1. Splice Sites: Where introns start and end.

2. Splice Site Usage: Which sites are actually used in a given tissue.

3. Splice Junctions: The specific linkage coordinates and their strength.⁴

2.4 Multimodal Output Heads

The final stage of the architecture consists of task-specific output heads. These are specialized neural network layers that take the processed representations from the decoder and generate predictions for specific biological assays. AlphaGenome features heads for 11 diverse modalities, ensuring a comprehensive functional profile.⁴

Modality Group	Specific Assays Predicted	Biological Insight Provided
Gene Expression	RNA-seq, CAGE, PRO-cap	Measures the abundance of mRNA; CAGE/PRO-cap pinpoint exact start sites of transcription.
Splicing	Splice sites, Junctions, Usage	Determines the structure of the mRNA transcript and protein isoforms.
Chromatin State	DNase-seq, ATAC-seq	Identifies "open" regions of DNA where regulatory proteins can bind.
Epigenetics	ChIP-seq (Histone marks)	Predicts chemical modifications (e.g., H3K27ac) that mark active enhancers or promoters.
Protein Binding	ChIP-seq (Transcription Factors)	Predicts where specific regulatory proteins (TFs) attach to DNA.
Genome Topology	Hi-C, Micro-C (Contact Maps)	Predicts the 3D folding and physical loops of the genome.

By predicting all these features simultaneously, AlphaGenome allows researchers to infer causal chains. For example, a variant might be predicted to disrupt a TF binding site (Modality 5), which causes a loss of chromatin accessibility (Modality 3), the disappearance of an enhancer mark (Modality 4), and finally a reduction in gene expression (Modality 1).

3. The Training Paradigm: From Pretraining to Distillation

The training of AlphaGenome was a massive computational undertaking, executed in two distinct stages designed to maximize both accuracy and inference efficiency.

3.1 Stage 1: Pretraining on the Reference Genome

The initial phase involved training the model on the reference genomes of humans (hg38) and mice (mm10). The training dataset was a vast compendium of functional genomic data sourced from major consortia like ENCODE (Encyclopedia of DNA Elements), GTEx (Genotype-Tissue Expression), FANTOM5, and the 4D Nucleome project.⁷

The researchers employed a 4-fold cross-validation scheme. The genome was divided into four parts; four different versions of the model were trained, each holding out a different quarter of the genome for validation.⁶ This ensured that the models were evaluated on DNA sequences they had never seen before, testing their ability to generalize rather than memorize. In addition to these "fold-specific" models, an ensemble of "all-folds" teacher models was trained on the entire dataset to maximize the total knowledge captured.⁶

This pretraining was performed on clusters of TPUv3 (Tensor Processing Units), leveraging the sequence parallelism described earlier. The training runs were computationally intensive, with fold-specific models training for approximately 15,000 steps.⁵

3.2 Stage 2: Knowledge Distillation

A significant challenge with large AI models is their deployment cost. Running an ensemble of massive models to analyze a single patient's genome—which contains millions of variants—would be prohibitively slow and expensive. To address this, the DeepMind team utilized Knowledge Distillation.⁹

In this process, the heavy "teacher" models (the ensemble trained in Stage 1) are used to train a single, lighter "student" model. The student model learns not from the raw data, but from the outputs of the teachers. Crucially, the student is trained using mutationally perturbed and augmented inputs.⁹

This means the student model is exposed to millions of synthetic DNA sequences containing random mutations, insertions, and deletions. The teacher models predict the effects of these mutations, and the student learns to mimic those predictions. This "active teaching" method has two profound benefits:

1. Robustness: The student sees far more genetic diversity than exists in the natural training data, learning to handle rare and novel variants more effectively.

2. Efficiency: The final student model captures the collective wisdom of the entire ensemble but runs as a single network.

The result is a model that is exceptionally fast. While the training required massive TPU pods, the distilled student model can perform inference—predicting variant effects across all 11 modalities—in less than one second on a single NVIDIA H100 GPU.⁹ This speed is a critical enabler for clinical applications where turnaround time is essential.

4. Benchmarking and Performance: Defining a New State-of-the-Art

To validate AlphaGenome, the researchers subjected it to a rigorous battery of benchmarks, comparing it against the strongest existing models in the field, including Borzoi (a previous DeepMind/Google model), Enformer, Orca, SpliceAI, and Pangolin.

The results, published in Nature, demonstrate that AlphaGenome has established a new state-of-the-art (SOTA) across the board. In a comprehensive evaluation of Variant Effect Prediction (VEP), AlphaGenome matched or exceeded the best competing models in 25 out of 26 evaluations.¹

4.1 Gene Expression and eQTLs

Predicting how a variant affects gene expression is the "holy grail" of regulatory genomics. AlphaGenome demonstrated significant gains over Borzoi, the previous leader in this space.

• Cell-Type Specificity: The model achieved a 14.7% relative improvement in predicting cell-type-specific gene expression levels.³

• eQTL Sign Prediction: For expression Quantitative Trait Loci (eQTLs), predicting the direction of the effect (does the variant increase or decrease expression?) is notoriously difficult. AlphaGenome improved upon Borzoi's performance by 25.5%.³

• Sensitivity: At a high-confidence threshold (yielding 90% accuracy), AlphaGenome recovered twice as many validated eQTLs (41%) as Borzoi (19%), demonstrating superior sensitivity in detecting subtle regulatory effects.³

4.2 Unraveling the 3D Genome

The 3D organization of the genome is critical for bringing distal enhancers into contact with promoters. Orca was previously considered the specialized standard for predicting these 3D contact maps.

• AlphaGenome outperformed Orca by 6.3% in overall contact map correlation.³

• More impressively, it showed a 42.3% improvement in predicting cell-type-specific differences in genome folding.³ This suggests AlphaGenome is far better at understanding how the genome refolds itself as a stem cell differentiates into a neuron or a muscle cell.

4.3 Splicing Precision

Despite not being a specialized splicing model, AlphaGenome's performance in this domain was formidable, driven by its 2D embedding architecture.

• It surpassed specialized tools like Pangolin and SpliceAI on 6 out of 7 splicing benchmarks.⁵

• It showed particular strength in predicting "deep intronic" variants—mutations located far from the exon boundaries that are often missed by models with shorter context windows.⁵

4.4 Polyadenylation

The model also excelled in predicting polyadenylation (the addition of a poly-A tail to RNA), achieving a Spearman correlation of 0.894 compared to Borzoi's 0.790.³ This process determines the stability and lifespan of mRNA molecules, adding another layer of regulatory insight.

5. Deep Dive: Deciphering the Splicing Code

One of the most compelling aspects of the AlphaGenome study is its demonstration of superior splicing prediction, a critical area for diagnosing rare diseases. Splicing mutations are estimated to cause up to one-third of all genetic diseases, yet they are frequently misclassified by standard clinical pipelines.

5.1 The "Nearest Gene" Fallacy: MELTF vs. DLG1

A pervasive heuristic in genomics is to assume that a regulatory variant affects the nearest gene. AlphaGenome exposes the limitations of this assumption through its analysis of a specific variant: chr3:197081044:TACTC>T, a 4-base-pair deletion.¹³

This variant is located in an intron of the DLG1 gene. A standard analysis would likely flag it as a potential regulator of DLG1. However, AlphaGenome's analysis of the entire locus revealed a different target. The model predicted that the variant's most profound effect was on the MELTF gene, where it caused a +2.57 log2 fold change in expression.¹⁴

Specifically, the model predicted that this deletion would cause exon skipping in MELTF. It identified:

• A substantial reduction in the usage of the canonical splice site.

• The loss of splice junctions linking the skipped exon.

• A strong decrease in RNA-seq coverage over the exon itself.¹³

• The emergence of a novel junction bypassing the exon.

This prediction aligned perfectly with experimental data from tibial artery tissue in the GTEx database, which confirmed the exon skipping event.¹³ This case study highlights AlphaGenome's ability to integrate data across large distances and identify the true targets of regulatory variants, correcting the misinterpretations that arise from simplified "nearest gene" models.

5.2 Tissue-Specific Splicing: CAMK2B

Splicing is often tissue-specific; a gene might include an exon in the brain but skip it in the heart. AlphaGenome demonstrated the ability to capture these nuances. In the case of the CAMK2B gene, the model accurately predicted splicing patterns that differed between neuronal and non-neuronal tissues.¹³

For a variant in this gene (chr7:44239589-44239663), AlphaGenome correctly predicted the tissue-regulated exon inclusion events, matching the observed RNA-seq data from GTEx.¹³ This ability to predict context-dependent splicing is crucial for understanding neurological disorders, where brain-specific isoforms are often the primary drivers of pathology.

6. Deep Dive: Unlocking Cancer Mechanisms

Cancer is fundamentally a disease of the genome, driven by the accumulation of mutations that alter cellular growth and survival. While "driver mutations" in coding regions (like BRCA1 or TP53) are well known, non-coding drivers have been harder to identify. AlphaGenome provides a powerful new tool for oncologists to decode these cryptic drivers.

6.1 The TAL1 Oncogene and Enhancer Hijacking

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer of the white blood cells. A known mechanism of oncogenesis in T-ALL is the activation of the TAL1 oncogene. In healthy cells, TAL1 is tightly regulated and often silent. In T-ALL, non-coding mutations can hijack this regulation.

The AlphaGenome researchers applied the model to a set of known non-coding mutations near TAL1. The model's unified predictions reconstructed the pathogenic mechanism with remarkable fidelity ¹:

1. Transcription Factor Binding: The model predicted that the specific mutations created a de novo binding motif for the MYB transcription factor. This is the initiating event—a "spark" created by the mutation.¹

2. Chromatin Remodeling: Consequently, the model predicted a local increase in H3K27ac and H3K4me1 histone modifications. These are the biochemical signatures of an active enhancer. Essentially, the mutation turned a piece of inactive DNA into a powerful switch.³

3. Gene Activation: Finally, the model predicted a surge in TAL1 gene expression driven by this new enhancer.¹⁵

This in silico reconstruction matches years of painstaking experimental work. The ability of AlphaGenome to predict this "enhancer hijacking" mechanism from sequence alone suggests it could be used to screen the genomes of cancer patients for similar, undiscovered non-coding drivers, potentially identifying new therapeutic targets.

7. Clinical and Research Implications

The introduction of AlphaGenome has immediate and far-reaching implications for both basic research and clinical medicine.

7.1 Improving Clinical Diagnostics (ClinVar)

Clinical geneticists rely on databases like ClinVar to interpret genetic tests. However, many variants in ClinVar are classified as "Variants of Uncertain Significance" (VUS) because their impact is unknown.

When tested against ClinVar data, AlphaGenome's composite scores consistently outperformed existing methods in distinguishing pathogenic variants from benign ones.¹⁶ This was true across multiple categories, including splice region variants and deep intronic variants. By providing a high-confidence prediction of functional impact, AlphaGenome could help reclassify VUSs, providing diagnoses for patients who currently lack answers.¹⁷

7.2 Synthetic Biology and Therapeutic Design

Beyond diagnosis, AlphaGenome is a design tool. In synthetic biology, researchers aim to engineer DNA sequences with specific properties—for example, a gene therapy vector that expresses a therapeutic protein only in liver cells to avoid toxicity in other tissues.

AlphaGenome's ability to predict cell-type-specific expression allows researchers to perform in silico evolution. They can digitally mutate a promoter sequence millions of times, using AlphaGenome to score the predicted expression in liver vs. non-liver cells, eventually converging on an optimal sequence before synthesizing a single molecule of DNA.¹⁷ This "design-test-learn" cycle, performed computationally, could drastically accelerate the development of gene therapies and mRNA vaccines.

7.3 Democratizing Access via Open Science

In a move to accelerate scientific progress, Google DeepMind has made AlphaGenome widely accessible. The model code and weights have been released on GitHub, and a web-based API allows researchers to submit sequences for analysis without needing their own high-performance computing infrastructure.¹

This openness stands in contrast to some previous proprietary models. It allows academic labs to integrate AlphaGenome into their own pipelines, finetune it on their specific datasets (e.g., a rare disease cohort), and validate its predictions independently.

8. Expert Perspectives and Critical Analysis

The release of AlphaGenome has elicited a wave of reaction from the scientific community, ranging from enthusiastic endorsement to cautious skepticism.

8.1 The Optimists: A "Major Milestone"

Dr. Robert Goldstone, Head of Genomics at the Francis Crick Institute, described the model as a "major milestone," noting that its high resolution moves the technology from "theoretical interest to practical utility".¹ He emphasized the feat of predicting expression solely from local DNA rules, calling it an "incredible technical feat".²⁰

Professor Kristian Helin, CEO of The Institute of Cancer Research, London, highlighted the model's potential to change how researchers generate hypotheses. He drew a parallel to AlphaFold, suggesting that while the immediate impact might be incremental, the long-term effect on understanding disease mechanisms will be transformative.²⁰

8.2 The Realists: "Not Ready for the Clinic"

Despite the excitement, experts caution against premature clinical deployment. Dr. Xianghua Li of King's College London warned that the model is "not yet reliable enough for patient care," noting that it can overstate risks for certain genetic changes and struggles with very rare variants where training data is sparse.²⁰

Professor Ben Lehner of the Wellcome Sanger Institute pointed out a fundamental limitation: Data Quality. "AI models are only as good as the data they are trained on," he noted. The current biological datasets (like ENCODE) are vast but still incomplete and noisy. The model cannot learn biology that hasn't been measured yet.²⁰

8.3 The Blind Spots

Several technical limitations remain:

• Single-Cell Resolution: AlphaGenome was largely trained on "bulk" tissue data (averages of millions of cells). It currently lacks the resolution to predict effects in rare cell types that might be diluted in bulk samples.²¹

• Structural Variants: While it handles small mutations well, its ability to predict the effects of massive chromosomal rearrangements (inversions, large duplications) is still being explored.

• Environmental Factors: Gene expression is not solely determined by DNA; it is also influenced by the environment (epigenetics, stress, diet). AlphaGenome only sees the DNA, meaning it captures the potential for expression, not necessarily the actual expression in a living human at a specific moment.²⁰

9. Future Horizons: Beyond the Sequence

AlphaGenome is not an endpoint but a foundation. The architecture—combining U-Nets, Transformers, and distillation—sets a blueprint for the next generation of genomic models.

Future iterations will likely focus on integrating single-cell ATAC-seq and RNA-seq data, allowing the model to predict regulatory effects at the level of individual cells. This would be a game-changer for understanding developmental biology and heterogeneous diseases like cancer.

Furthermore, the integration of AlphaGenome with protein structure models (like AlphaFold) could create a true "end-to-end" simulation of biology: predicting how a DNA mutation alters RNA splicing, how that alters the protein structure, and how that altered protein changes cellular function.

10. Conclusion

The publication of AlphaGenome in Nature is a watershed moment for genomics. By successfully unifying the prediction of gene expression, splicing, and chromatin architecture into a single, high-resolution model, Google DeepMind has provided the most complete decoder yet for the human regulatory genome.

While challenges in clinical validation and data granularity remain, the model's performance—surpassing state-of-the-art benchmarks in 96% of evaluations—establishes it as the new standard in the field. For the researcher staring at a list of thousands of non-coding variants, AlphaGenome offers a powerful new lens, turning a string of A's, C's, G's, and T's into a dynamic map of biological function. As the community adopts and refines this tool, we move one step closer to fulfilling the promise of the Human Genome Project: not just reading the code of life, but truly understanding it.

Metric	AlphaGenome Specification
Input Context	1,000,000 base pairs (1 Mb)
Resolution	Single base pair (1 bp)
Output Modalities	11 (Expression, Splicing, Accessibility, etc.)
Tracks Predicted	5,930 (Human), 1,128 (Mouse)
Inference Speed	< 1 second per variant (NVIDIA H100)
Training Hardware	TPUv3 Pods (Pretraining)
Benchmark Success	25/26 Variant Effect Prediction tasks 12

Works cited

1. New Nature Cover: Google's Alpha Series Newcomer Instantly Grasps Life's Ultimate Blueprint, accessed January 29, 2026, https://eu.36kr.com/en/p/3659278714839936

2. Genomics: AlphaGenome predicts the impact of DNA variations (Nature), accessed January 29, 2026, https://www.natureasia.com/en/info/press-releases/detail/9222

3. AlphaGenome: One Model for the Other 98% of Your DNA | rewire.it, accessed January 29, 2026, https://rewire.it/blog/alphagenome-one-model-for-the-other-98-percent-of-your-dna/

4. google/alphagenome-all-folds - Hugging Face, accessed January 29, 2026, https://huggingface.co/google/alphagenome-all-folds

5. How AlphaGenome Models Gene Regulation: 2D Embeddings, Splicing, and the Race to Read Non-Coding DNA | rewire.it, accessed January 29, 2026, https://rewire.it/blog/alphagenome-gene-regulation-2d-embeddings-splicing-noncoding-dna

6. AlphaGenome: advancing regulatory variant effect prediction with a unified DNA sequence model - bioRxiv, accessed January 29, 2026, https://www.biorxiv.org/content/10.1101/2025.06.25.661532v1.full.pdf

7. InternScience/SGI-IdeaGeneration · Datasets at Hugging Face, accessed January 29, 2026, https://huggingface.co/datasets/InternScience/SGI-IdeaGeneration

8. AlphaGenome: Google DeepMind's Breakthrough Model for Predicting DNA - Medvolt | AI, accessed January 29, 2026, https://www.medvolt.ai/blog/google-deepmind-alphagenome-dna-variant-effect-prediction-deepmind

9. AlphaGenome: advancing regulatory variant effect prediction with a unified DNA sequence model | bioRxiv, accessed January 29, 2026, https://www.biorxiv.org/content/10.1101/2025.06.25.661532v2.full-text

10. Google | AlphaGenome | Kaggle, accessed January 29, 2026, https://www.kaggle.com/models/google/alphagenome

11. DeepMind Unveils AlphaGenome: Predict Variant Effects Across All Modalities and Cell Types in One Second - 36氪, accessed January 29, 2026, https://eu.36kr.com/en/p/3352933207978624

12. How variant scoring works - AlphaGenome, accessed January 29, 2026, https://www.alphagenomedocs.com/variant_scoring.html

13. AlphaGenome: advancing regulatory variant effect prediction with a unified DNA sequence model | bioRxiv, accessed January 29, 2026, https://www.biorxiv.org/content/10.1101/2025.06.25.661532v1.full-text

14. AlphaGenome Tutorial - BioMCP, accessed January 29, 2026, https://biomcp.org/tutorials/claude-code-biomcp-alphagenome/

15. DeepMind's AlphaGenome cracks the code of non-coding DNA with unprecedented precision - Clinical Laboratory int., accessed January 29, 2026, https://clinlabint.com/deepminds-alphagenome-cracks-the-code-of-non-coding-dna-with-unprecedented-precision/

16. Google AI's Major Breakthrough in DNA: AlphaGenome Decodes the Book of Life - Medium, accessed January 29, 2026, https://medium.com/@chronohack/google-ais-major-breakthrough-in-dna-alphagenome-decodes-the-book-of-life-346348c4cbe1

17. AI tool AlphaGenome predicts how one typo can change a genetic story, accessed January 29, 2026, https://www.sciencenews.org/article/ai-tool-alphagenome-predicts-genetics

18. AlphaGenome: AI for better understanding the genome - Google DeepMind, accessed January 29, 2026, https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome/

19. google-deepmind/alphagenome_research: Research code accompanying AlphaGenome - GitHub, accessed January 29, 2026, https://github.com/google-deepmind/alphagenome_research

20. expert reaction to paper on Google DeepMind’s AlphaGenome, accessed January 29, 2026, https://www.sciencemediacentre.org/expert-reaction-to-paper-on-google-deepminds-alphagenome/

21. AlphaGenome: AI for better understanding the genome : r/singularity - Reddit, accessed January 29, 2026, https://www.reddit.com/r/singularity/comments/1lk6l28/alphagenome_ai_for_better_understanding_the_genome/